Prognostic factors of paraneoplastic pemphigus

Arch Dermatol. 2012 Oct;148(10):1165-72. doi: 10.1001/archdermatol.2012.1830.

Abstract

Objective: To identify the prognostic factors of overall survival in a series of patients with paraneoplastic pemphigus (PNP).

Design: Multicenter retrospective cohort study.

Setting: Twenty-seven dermatology departments in France.

Patients: A total of 53 patients (31 men and 22 women; median age, 59 years; age range, 30-88 years) were diagnosed as having PNP between 1992 and 2010.

Main outcome measures: Overall Kaplan-Meier survival rates were estimated, and features associated with survival were assessed using univariate (log-rank test) and multivariate (Cox regression) analyses.

Results: The study included 53 patients with PNP. Thirty-six patients (68%) died during the study. The 1-, 3-, and 5-year overall survival rates were 49%, 41%, and 38%, respectively. The main causes of death were infections (n=21) and evolution of neoplasia (n=6). In univariate analysis, the main detrimental prognostic factors identified were erythema multiforme–like skin lesions (P=.05) and histologic keratinocyte necrosis (P=.03). None of the 5 patients with Castleman disease died during the study. After adjustment for age and sex in multivariate analysis, erythema multiforme–like skin lesions remained predictive of fatal outcome, with a 2-fold increase in death rate (hazard ratio [HR], 2.3; 95% CI, 1.05-5.03; P=.04). The prognosis of patients with PNP was even poorer when erythema multiforme–like skin lesions were associated with severe skin or mucosal involvement at presentation (HR of death, 3.0; 95% CI, 1.01-8.92; P=.049).

Conclusion: Patients with PNP with erythema multiforme–like skin lesions and histologic keratinocyte necrosis, especially when associated with extensive lesions at presentation, are likely to have a more severe and rapid fatal outcome and should be managed very carefully.

Publication types

  • Multicenter Study

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Autoantibodies / blood
  • Carrier Proteins / immunology
  • Cytoskeletal Proteins / immunology
  • Desmoplakins / immunology
  • Dystonin
  • Erythema Multiforme / pathology*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Kaplan-Meier Estimate
  • Male
  • Membrane Proteins / immunology
  • Middle Aged
  • Mucous Membrane / pathology
  • Multivariate Analysis
  • Neoplasms / complications*
  • Nerve Tissue Proteins / immunology
  • Paraneoplastic Syndromes / drug therapy
  • Paraneoplastic Syndromes / immunology
  • Paraneoplastic Syndromes / pathology*
  • Pemphigus / drug therapy
  • Pemphigus / immunology
  • Pemphigus / pathology*
  • Plakins / immunology
  • Prognosis
  • Proportional Hazards Models
  • Protein Precursors / immunology
  • Retrospective Studies
  • Rituximab
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal, Murine-Derived
  • Autoantibodies
  • Carrier Proteins
  • Cytoskeletal Proteins
  • DST protein, human
  • Desmoplakins
  • Dystonin
  • Immunologic Factors
  • Immunosuppressive Agents
  • Membrane Proteins
  • Nerve Tissue Proteins
  • PPL protein, human
  • Plakins
  • Protein Precursors
  • envoplakin
  • Rituximab